New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir

References

• Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010;14(1):1–21, vii.
   PubMedGoogle Scholar
• WHO hepatitis C fact sheet, No 164. [Internet]; [updated 2015 Jul; cited 2015 Dec 1]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/
   Google Scholar
• Denniston MM, Jiles RB, Drobeniuc J. Chronic hepatitis C virus infection in the United States, national health and nutrition examination survey 2003 to 2010. Ann Intern Med. 2014;160(5):293–300.
   PubMed Web of Science ®Google Scholar
• Screening for hepatitis C virus infection in adults clinical summary of U.S. preventive services task force recommendation; 2013 [cited 2015 Dec 1]. Available from: http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/hepatitis-c-screening
   Google Scholar
• Hepatitis C information for healthcare professionals [Internet]. Center for Disease Control and Prevention. US Department of Health and Human Services; 2015 [cited 2015 Oct 14]. Available from: http://Www.Cdc.Gov/Hepatitis/Hcv/Hcvfaq.Htm
   Google Scholar
• Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43(6):1303–1310.
   PubMed Web of Science ®Google Scholar
• Gentile I, Coppola N, Pasquale G, et al. A simple noninvasive score based on routine parameters can predict liver cirrhosis in patients with chronic hepatitis C. Hepat Mon. 2013;13(5):e8352.
   PubMed Web of Science ®Google Scholar
• AASLD guidelines: AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C; [cited 2015 Dec 1]. Available from: http://www.hcvguidelines.org
   Google Scholar
• Jazwinski A, Muir AJ. Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol Hepatol. 2011;7(3):154–162.
   PubMedGoogle Scholar
• Ge D, Fellay J, Thompson A. Genetic variation in Il28b predicts hepatitis C treatment-induced viral clearance. Nat Rev Gastroenterol Hepatol. 2009;461:399–401.
   Google Scholar
• Poynard T, Mchutchinson J, Goodman Z, et al. Is an ‘‘a ` La Carte’’ combination interferon Alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology. 2000;31:211–218.
   PubMed Web of Science ®Google Scholar
• Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection. J Family Community Med. 2013;20(1):35–40.
   PubMedGoogle Scholar
• Parfieniuk A, Jaroszewicz J, Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus. World J Gastroenterol. 2007;13(43):5673–5681.
   PubMed Web of Science ®Google Scholar
• Pegasys [Package Insert]. South San Francisco, CA: Hoffmann-La Roche Inc; 2002 [reviced 2014 sep; cited Dec 1 2015]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/pegihof101602lb.htm
   Google Scholar
• Rebetol [Package Insert]. Whitehouse Station, NJ: Merck & Co Inc; 1998 [reviced Dec 2014; cited Dec 1 2015]. Available from: https://www.merck.com/product/usa/pi_circulars/r/rebetol/rebetol_pi.pdf
   Google Scholar
• Victrelis [Package Insert]. Whitehouse Station, NJ: Merck & Co Inc; 2011 [revised 2011 may; cited 2015 Dec 2]. Available from: https://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf
   Google Scholar
• Incivek [Package Insert]. Cambridge, MA: Vertex Pharmaceuticals Inc; 2011 [revised 2012 Dec; cited 2015 Dec 2]. Available from: http://pi.vrtx.com/files/uspi_telaprevir.pdf
   Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV 1 infection. N Engl J Med. 2011;364(13):1207–1217.
   PubMed Web of Science ®Google Scholar
• Poordad F, Mccone J, Bacon B, et al. Boceprevir for untreated chronic HCV 1 infection. N Engl J Med. 2011;364(13):1195–1206.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telapravir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417–2428.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Mchutchinson JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–2416.
   PubMed Web of Science ®Google Scholar
• Ghany MG, Nelson DR, Strader DB, et al. American association for study of liver diseases, an update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the study of liver diseases. Hepatology. 2011;54(4):1433–1444.
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature. 2005;436(7053):933–938.
   PubMed Web of Science ®Google Scholar
• Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol. 2013;11(7):482–496.
   PubMed Web of Science ®Google Scholar
• Schinazi R, Halfon P, Marcellin P, et al. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int. 2014;34(Suppl. 1):69–78.
   PubMed Web of Science ®Google Scholar
• Kumar S, Jacobson IM. Antiviral therapy with nucleotide polymerase inhibitors for chronic hepatitis C. J Hepatol. 2014;61(1 Suppl):S91–7.
   PubMed Web of Science ®Google Scholar
• Berger C, Romero-Brey I, Radujkovic D, et al. Daclatasvir-like inhibitors of NS5a block early biogenesis of hepatitis c virus-induced membranous replication factories, independent of RNA replication. Gastroenterology. 2014;147(5):1094–105 e25.
   PubMed Web of Science ®Google Scholar
• Gao M. Antiviral activity and resistance of HCV NS5a replication complex inhibitors. Curr Opin Virol. 2013;3(5):514–520.
   PubMed Web of Science ®Google Scholar
• Eyre NS, Beard MR. HCV NS5a inhibitors disrupt replication factory formation: a novel mechanism of antiviral action. Gastroenterology. 2014;147(5):959–962.
   PubMedGoogle Scholar
• Nakamoto S, Kanda T, Wu S, et al. Hepatitis C virus NS5a inhibitors and drug resistance mutations. World J Gastroenterol. 2014;20(11):2902–2912.
   PubMed Web of Science ®Google Scholar
• Sovaldi [Package Insert]. Foster City, CA: Gilead Sciences Inc; 2013 [revised 2014 Nov; cited 2015 Dec 2]. Available from: http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf
   Google Scholar
• Keating GM, Vaidya A. Sofosbuvir: first global approval. Drugs. 2014;74(2):273–282.
   PubMed Web of Science ®Google Scholar
• Koff RS. The efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5b polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2014;39(5):478–487.
   PubMed Web of Science ®Google Scholar
• Tong X, Le Pogam S, Li L, et al. In vivo emergence of a novel mutant L159f/L320f in the NS5b polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis. 2014;209(5):668–675.
   PubMed Web of Science ®Google Scholar
• Kirby BJ, Symonds WT, Kearney BP, et al. Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5b polymerase inhibitor sofosbuvir. Clin Pharmacokinet. 2015;54(7):677–690.
   PubMed Web of Science ®Google Scholar
• Harvoni [Package Insert]. Foster City, CA: Gilead Sciences Inc; 2014 [revised 2014 Oct; cited 2015 Feb 12]. Available from: https://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf
   Google Scholar
• Gentile I, Buonomo AR, Borgia F. Ledipasvir: a novel synthetic antiviral for the treatment of HCV infection. Expert Opin Investig Drugs. 2014;23(4):561–571.
   PubMed Web of Science ®Google Scholar
• Olysio [Package Insert]. Titusville, NJ: Janssen Therapeutics; 2013 [revised 2014 Nov; cited 2015 Feb 12]. Available from: https://www.olysio.com/shared/product/olysio/prescribing-information.pdf
   Google Scholar
• Daklinza [Package Insert]. Princeton, NJ: Bristol-Meyers Squibb Company; 2015 [revised 2015 Jul 24; cited 2015 Dec 2]. Available from: Packageinserts.Bms.Com/Pi/Pi_Daklinza.Pdf
   Google Scholar
• Viekira Pak [Package Insert]. North Chicago, IL: Abbvie Inc; 2014 [revised Feb 2015; cited 2015 Dec 2]. Available from: http://Www.Accessdata.Fda.Gov/Drugsatfda_Docs/Label/2014/206619lbl.Pdf
   Google Scholar
• Klibanov OM, Gale SE, Santevecchi B. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. Ann Pharmacother. 2015;49(5):566–581.
   PubMed Web of Science ®Google Scholar
• Smith MA, Regal RE, Mohammad RA. Daclatasvir: a NS5a replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016;50(1):39–46.
   Web of Science ®Google Scholar
• Tischer S, Fontana RJ. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol. 2014;60(4):872–884.
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Burton JR Jr, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:596–606.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M, Lawitz E, Kowdley KV, et al. Sofosbuvir (Gs-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol. 2013;58(4):663–668.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34–44.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13(5):401–408.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (atomic): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013;381(9883):2100–2107.
   PubMed Web of Science ®Google Scholar
• Lawitz EJ, Rodriguez-Torres M, Denning J, et al. All-oral therapy with nucleotide inhibitors sofosbuvir and gs-0938 for 14 days in treatment-naive genotype 1 hepatitis C (Nuclear). J Viral Hepat. 2013;20(10):699–707.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with hiv coinfection. JAMA. 2014;312(4):353–361.
   PubMed Web of Science ®Google Scholar
• Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148(1):108–117.
   PubMed Web of Science ®Google Scholar
• Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of hcv infection after liver transplantation: an open-label study. Gastroenterology. 2015;148(1):100–107 e1.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–1887.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–1877.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993–2001.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (Lonestar): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515–523.
   PubMed Web of Science ®Google Scholar
• Osinusi A, Kohli A, Marti MM, et al. Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study. Ann Intern Med. 2014;161(9):634–638.
   PubMed Web of Science ®Google Scholar
• Kohli A, Osinusi A, Sims Z, et al. Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2a cohort study. Lancet. 2015;385(9973):1107–1113.
   PubMed Web of Science ®Google Scholar
• Wyles DL, Rodriguez-Torres M, Lawitz E, et al. All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naive patients with genotype 1 HCV infection. Hepatology. 2014;60(1):56–64.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–1898.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–1493.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–1888.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, An D, Pang PS, et al. Analysis of subgroup differences in the ion-3 trial of ledipasvir-sofosbuvir in chronic hepatitis C infection. Open Forum Infect Dis. 2015;2(2):ofv056.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–221.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ally-3 phase iii study. Hepatology. 2015;61(4):1127–1135.
   PubMed Web of Science ®Google Scholar
• Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):714–725.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the cosmos randomised study. Lancet. 2014;384(9956):1756–1765.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (Quest-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384(9941):403–413.
   PubMed Web of Science ®Google Scholar
• Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (quest-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384(9941):414–426.
   PubMed Web of Science ®Google Scholar
• Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 Who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146(7):1669–79 e3.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with Abt-450/R-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594–1603.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with Abt-450/R-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604–1614.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Bernstein D, Lalezari J, et al. Abt-450/R-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983–1992.
   PubMed Web of Science ®Google Scholar
• Poordad F, Hezode C, Trinh R, et al. Abt-450/R-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973–1982.
   PubMed Web of Science ®Google Scholar
• Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371(25):2375–2382.
   PubMed Web of Science ®Google Scholar
• Ohkoshi S, Hirono H, Yamagiwa S. Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosis. World J Gastrointest Pharmacol Ther. 2015;6(4):114–119.
   PubMedGoogle Scholar
• Righi E, Londero A, Carnelutti A, et al. Impact of new treatment options for hepatitis C virus infection in liver transplantation. World J Gastroenterol. 2015;21(38):10760–10775.
   PubMed Web of Science ®Google Scholar
• Carvalho-Filho RJ, Feldner AC, Silva AE, et al. Management of hepatitis C in patients with chronic kidney disease. World J Gastroenterol. 2015;21(2):408–422.
   PubMed Web of Science ®Google Scholar
• Del Bello D, Ita Nagy F, Hand J, et al. Direct-acting antiviral-based therapy for chronic hepatitis C virus in HIV-infected patients. Curr Opin HIV AIDS. 2015;10(5):337–347.
   PubMed Web of Science ®Google Scholar
• Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015;162(6):407–419.
   PubMed Web of Science ®Google Scholar
• Walker J. Expensive hepatitis C medications drive prescription-drug spending. The Wall Street Journal. 2015 Mar 10 [cited 2015 Aug 26]. Available from: http://www.wsj.com/articles/expensive-hepatitis-c-medications-drive-prescription-drug-spending-1425960214
   Google Scholar
• De Clercq E. current race in the development of Daas (Direct-Acting Antivirals) against HCV. Biochem Pharmacol. 2014;89(4):441–452.
   PubMed Web of Science ®Google Scholar
• Hill A, Cooke G. Hepatitis C can be cured globally, but at what cost? Science. 2014;345(6193):141–142.
   PubMed Web of Science ®Google Scholar
• Cohen J. advocates protest the cost of a hepatitis C cure. Science. 2013;342:1302–1303.
   PubMed Web of Science ®Google Scholar
• Steinbrook R, Redberg R. The high price of the new hepatitis C virus drugs. JAMA Intern Med. 2014;174(7):1172.
   PubMed Web of Science ®Google Scholar